Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT03675737 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1579

Enrollment

INDUSTRY

Sponsor class

Conditions

Stomach Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin
DRUG: 5-fluorouracil
DRUG: oxaliplatin
DRUG: capecitabine
DRUG: Placebo for Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC